Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer
- 20 December 2006
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 60 (10), 1112-1116
- https://doi.org/10.1136/jcp.2006.044537
Abstract
Cut-off scores for determining positivity of biomarkers detected by immunohistochemistry are often set arbitrarily and vary between reports.To evaluate the performance of receiver operating characteristic (ROC) curve analysis in determining clinically important cut-off scores for a novel tumour marker, the receptor for hyaluronic acid mediated motility (RHAMM), and show the reproducibility of the selected cut-off scores in 1197 mismatch-repair (MMR) proficient colorectal cancers (CRC).Immunohistochemistry for RHAMM was performed using a tissue microarray of 1197 MMR-proficient CRC. Immunoreactivity was scored using a semi-quantitative scoring method by evaluating the percentage of positive tumour cells. ROC curve analysis was performed for T stage, N stage, tumour grade, vascular invasion and survival. The score with the shortest distance from the curve to the point with both maximum sensitivity and specificity, i.e. the point (0.0, 1.0), was selected as the cut-off score leading to the greatest number of tumours correctly classified as having or not having the clinical outcome. In order to determine the reliability of the selected cut-off scores, 100 bootstrapped replications were performed to resample the data.The cut-off score for T stage, N stage, tumour grade and vascular invasion was 100% and that for survival 90%. The most frequently selected cut-off score from the 100 resamples was also 100% for T stage, N stage, tumour grade, and vascular invasion and 90% for survival.ROC curve analysis can be used as an alternative method in the selection and validation of cut-off scores for determining the clinically relevant threshold for immunohistochemical tumour positivity.Keywords
This publication has 33 references indexed in Scilit:
- Impact of EGFR expression on colorectal cancer patient prognosis and survivalAnnals of Oncology, 2005
- Evaluating operative risk in colorectal cancer surgery: ASA and POSSUM-based predictive modelsSurgical Oncology, 2004
- Rectal Cancer: Local Staging and Assessment of Lymph Node Involvement with Endoluminal US, CT, and MR Imaging—A Meta-AnalysisRadiology, 2004
- Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor TissuesJournal of Histochemistry & Cytochemistry, 2004
- CEA, CA 242, CA 19-9, CA 72-4 and hCGβ in the Diagnosis of Recurrent Colorectal CancerTumor Biology, 2004
- Thymidylate Synthase Expression, p53, bcl-2, Ki-67 and p27 in Colorectal Cancer: Relationships with Tumor Recurrence and SurvivalTumor Biology, 2004
- Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma.1999
- p53, vessel count, and vascular endothelial growth factor expression in human colon cancerInternational Journal of Cancer, 1998
- Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasisInternational Journal of Cancer, 1997
- Receiver operating characteristic (ROC) methodology: the state of the art.1989